Migraine — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for migraine. 36 active patents protecting 3 drugs from 3+ originators. First major cliff: 2033. Daily refresh.

3
Approved drugs
36
Active US patents
54/100
Avg vulnerability
$2.1B
Annual revenue covered

Originators in Migraine

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

AbbVie 27 patents GSK 6 patents Pfizer 3 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating migraine. Each bar = one year. Y-axis scaled to peak year (14 patents).

5
30
5
31
2
32
3
33
1
34
14
35
1
39

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Ubrelvy
UBROGEPANT
 AbbVie 27 56 $664M 2031-11-10
Imitrex
SUMATRIPTAN
 GSK 6 63 — 2030-06-16
Nurtec Odt
Rimegepant Sulfate
 Pfizer 3 43 $1.4B 2033-02-25

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
11337962 Imitrex method of use 76 2030-06-16
12329750 Ubrelvy method of use 75 2041-12-22
12194030 Ubrelvy method of use 75 2041-12-22
12070450 Ubrelvy method of use 75 2041-12-22
11857542 Ubrelvy method of use 75 2041-12-22
11717515 Ubrelvy method of use 70 2041-12-22
10603305 Imitrex method of use 68 2030-06-16
9974770 Imitrex method of use 68 2030-06-16
9610280 Imitrex method of use 68 2030-06-16
9211282 Imitrex method of use 68 2031-07-19

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
8912210 Ubrelvy composition of matter 4 2033-12-23
8912210 Ubrelvy composition of matter 4 2033-12-23
8759372 Nurtec Odt composition of matter 4 2033-02-25
10117836 Ubrelvy formulation 42 2035-01-30
10117836 Ubrelvy formulation 42 2035-01-30
12458633 Ubrelvy formulation 55 2035-01-30
12310953 Ubrelvy formulation 55 2035-01-30
11925709 Ubrelvy formulation 55 2035-01-30
12220408 Ubrelvy formulation 55 2035-01-30
12220408 Ubrelvy formulation 55 2035-01-30

Related